A randomized trial is conducted to evaluate the efficacy of a new cholesterol-lowering medication. The primary outcome is incident coronary artery disease. Participants are free of coronary artery disease at the start of the study and randomized to receive either the new medication or a placebo. Participants are followed for a maximum of 10 years for the development of coronary artery disease. The following data are observed below. Compute the relative risk of coronary artery disease in patients receiving the new medication as compared to those receiving a placebo.

	Number of Participants	Number with Coronary Artery Disease
Cholesterol medication	500	30
Placebo	500	50

The choices are

0.6

1

2

0.4